AKT1 and Alzheimer disease: Exendin-4 has been shown to reduce levels of Aβ and cholinergic dysfunction in memory-sensitive brain areas of AD rat models, and the action was mediated by the PI3K/Akt pathway (Garabadu and Verma, 2019).